An updated systematic review across more than 20,000 pediatric sepsis patients reported that balanced crystalloids reduce hyperchloremia and renal replacement therapy compared with normal saline, without changing overall survival. The evidence synthesis is aimed at electrolyte-driven complications and downstream kidney outcomes. The clinical signal supports continued consideration of fluid choice in pediatric sepsis pathways, with the review reinforcing that biochemical endpoints like hyperchloremia translate into renal resource utilization differences. For companies developing IV solutions or sepsis-support products, the update underscores how comparative fluid effects remain a major mechanistic lever in critical care—especially where kidney injury avoidance matters for both outcomes and cost.